Erythropoiesis-stimulating agents (ESAs), such as recombinant human erythropoietin (EPO), have been used to treat anaemia in patients with MDS; ESAs constitute an important therapeutic alternative since they reduce transfusion requirements and the risks associated with transfusions 3. Here, EPO is linked to anemia.